TransMedics Reports Third-Quarter 2026 Results, Raises Full-Year Guidance
TransMedics said strong revenue generation drove an increase in its full-year 2026 guidance.
Story updates
09:03:15 PM UTC
SquawkNews
TransMedics Group, Inc. (TMDX) Raises 2026 Revenue Guidance to $764M–$774M
09:03:43 PM UTC
SquawkNews
TransMedics reported third-quarter 2026 revenue of $203.0 million, up 41% year over year, and raised its full-year revenue guidance to $764 million to $774 million, including PAD Aviation. Net income was $17.1 million, while adjusted diluted earnings per share were $0.51. The company also reported…
Strong Revenue Generation Drives Increase in Full-Year 2026 Guidance; Recent Progress Positions Company for Continued Growth with Several Near- and Mid-Term CatalystsANDOVER, Mass., Nov. 5, 2026 // -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company tha…